[저자] Filippo Pieralli, Fulvio Pomero, Francesco Dentali, Claudio Norbiato, Tiziana Attardo, Susanna Vicari, Elena Magnani, Maria Antonietta Marzilli, Paola Piccolo, Antonella Valerio, Dario Manfellotto,
on behalf of FADOI RECOVER Study GroupBrugiottiElena4CarellaVincenzo4CoppoMartina4FerrandoFrancesca4LauritanoMarta.4MarchettiBruno4VitaleFrancesco4GasperinaDaniela Dalla5BaroniElena6BoccatondaAndrea6GiorginiEnrico7MiliteTeresa7MontagutiLuca7CagnoniElisa8MogaveroGiulia8CapoccettaGiovanni9De GiovanniRaffaella11MartelliFrancesca11GuazziniGiulia1GrassiAlberto12RomaniLaura12GnerrePaola13MastroianniFranco14D’OnofrioFabiana14BerraSergio15PozzoliSimona15BobbioFlavio16BiancoSara16ReAzzurra16LiberatoNicola17JobSara17AntonucciGiancarlo18ParaOmbretta19FerraraGino20GiordanoAntonietta20FalcoOlga21ManettiRoberto21BolognaCarolina22BuscagliaSandra23OlivieroCristina2AmitranoMaria24IorioValeria24TibulloLoredana24FerrariGiovanni25BrandoliniMicaela25LeoneGiovanna26UsaiCarlo27ManzoniNoemi Elisabetta27Di StefanoRita28RennaEusapia28segreteria@fadoi.org, Elena Brugiotti, Vincenzo Carella, Martina Coppo, Francesca Ferrando, Marta. Lauritano, Bruno Marchetti, Francesco Vitale, Daniela Dalla Gasperina, Elena Baroni, Andrea Boccatonda, Enrico Giorgini, Teresa Milite, Luca Montaguti, Elisa Cagnoni, Giulia Mogavero, Giovanni Capoccetta, Raffaella De Giovanni, Francesca Martelli, Giulia Guazzini, Alberto Grassi, Laura Romani, Paola Gnerre, Franco Mastroianni, Fabiana D’Onofrio, Sergio Berra, Simona Pozzoli, Flavio Bobbio, Sara Bianco, Azzurra Re, Nicola Liberato, Sara Job, Giancarlo Antonucci, Ombretta Para, Gino Ferrara, Antonietta Giordano, Olga Falco, Roberto Manetti, Carolina Bologna, Sandra Buscaglia, Cristina Oliviero, Maria Amitrano, Valeria Iorio, Loredana Tibullo, Giovanni Ferrari, Micaela Brandolini, Giovanna Leone, Carlo Usai, Noemi Elisabetta Manzoni, Rita Di Stefano, Eusapia Renna
Background Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. Methods This retrospective observational multicenter study included consecutive patients, hospitalized for moderate-to-severe COVID-19 (September 2020—September 2021), who were treated with remdesivir. Results One thousand four patients were enrolled, all with onset of symptoms occurring less than 10 days before starting remdesivir; 17% of patients had 4 or more concomitant diseases. Remdesivir was well tolerated, adverse drug reactions (ADRs) being reported in 2.3% of patients. In-hospital death occurred in 80 patients (8.0%). The median timing of the first remdesivir dose was 5 days after symptom onset. The following endpoints did not differ according to the time span from the onset of symptoms to the first dose: length of hospitalization, in-hospital death, composite outcome (in-hospital death and/or endotracheal intubation). Advanced age, number of comorbidities ≥ 4, and severity of respiratory failure at admission were associated with poor in-hospital outcomes. Conclusion In a real-world setting, remdesivir proved to be a safe and well-tolerated treatment for moderate-to-severe COVID-19. In patients receiving remdesivir less than 3 or 5 days from the onset of SARS-CoV-2 symptoms, mortality and the need for mechanical ventilation did not differ from the rest of the sample.
All Keywords
【저자키워드】 COVID-19 pneumonia, Remdesivir, internal medicine, management of COVID-19,